Benjamin F. Edwards & Company’s BioCryst Pharmaceuticals BCRX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-700	Closed	-$10K	–	1704
2021 Q3	$10K	Hold	700	–	–	﹤0.01%	1369
2021 Q2	$11K	Sell	700 -300	-30%	-$4.08K	﹤0.01%	1355
2021 Q1	$10K	Hold	1,000	–	–	﹤0.01%	1348
2020 Q4	$7K	Hold	1,000	–	–	﹤0.01%	1335
2020 Q3	$3K	Hold	1,000	–	–	﹤0.01%	1500
2020 Q2	$5K	Hold	1,000	–	–	﹤0.01%	1409
2020 Q1	$2K	Hold	1,000	–	–	﹤0.01%	1575
2019 Q4	$3K	Hold	1,000	–	–	﹤0.01%	1696
2019 Q3	$3K	Hold	1,000	–	–	﹤0.01%	1667
2019 Q2	$4K	Hold	1,000	–	–	﹤0.01%	1655
2019 Q1	$8K	Buy	+1,000	New	+$8.56K	﹤0.01%	1366

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Benjamin F. Edwards & Company's BCRX Position: Q4 2021 in Review

Benjamin F. Edwards & Company sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2021, closing a stake of 700 shares — an estimated $10K sold.

Benjamin F. Edwards & Company first reported a position in BCRX in Q1 2019 and held it in 11 quarters. The position peaked at $11K in Q2 2021. 206 funds tracked by Wall St. Rank hold BCRX as of Q4 2021.

Benjamin F. Edwards & Company reported no remaining BioCryst Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Benjamin F. Edwards & Company sold 700 BioCryst Pharmaceuticals shares in Q4 2021, an estimated $10K.
Benjamin F. Edwards & Company first reported a position in BioCryst Pharmaceuticals in Q1 2019 and held it in 11 quarters.
Benjamin F. Edwards & Company's BioCryst Pharmaceuticals position peaked at $11K in Q2 2021.
206 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2021.

Based on Benjamin F. Edwards & Company's 13F filing for Q4 2021, filed 7 Feb 2022.